Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01938079 · ClinicalTrials.gov registry record · NA
Pharmacokinetic Alterations During ECMO
A NA study, sponsored by Columbia University.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT01938079 is a NA study that has completed, run by Columbia University. The registered enrollment target is 20 participants.
The verdict
NCT01938079, a NA study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
In a healthy patient, the lungs provide oxygen to the blood and remove carbon dioxide. However, in patients with severe lung failure, blood may not adequately be delivered to the lungs, or the lungs may not adequately supply blood with oxygen. In this case, patients may require assistance from a machine to help provide this oxygen. Extracorporeal membrane oxygenation (ECMO) is a device that acts as an artificial lung, allowing the patient to recover from their illness. Patients receiving support from ECMO are often put in a medically induced coma while their lungs heal. Certain drugs may stick to the internal surfaces of the machine; therefore leading to decreased concentrations. Patients receiving ECMO often require high doses of both pain medications and sedatives in order to provide comfort. Low doses of a drug, ketamine, may help to provide additive effects to pain relief and allow lower doses of other pain medications. The hypothesis is that patients treated with continuous intravenous ketamine, will have lower requirements of other pain medications while receiving ECMO for acute respiratory failure while achieving the desired level of sedation.
Interventions
- DRUG Ketamine
- OTHER Sedative drug regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-09 |
| Est. Completion | 2015-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01938079
The ClinicalTrials.gov registry entry for NCT01938079 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ketamine is the first listed.
NCT01938079 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01938079 about?
NCT01938079 is a clinical study titled "Pharmacokinetic Alterations During ECMO". In a healthy patient, the lungs provide oxygen to the blood and remove carbon dioxide. However, in patients with severe lung failure, blood may not adequately be delivered to the lungs, or the lungs may not adequately supply blood with oxygen. In this case, patients may require assistance from a mac...
What is the current status of trial NCT01938079?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2013-09. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01938079?
The interventions under investigation include: Ketamine (DRUG), Sedative drug regimen (OTHER).
Who is sponsoring clinical trial NCT01938079?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.